P/B
7,6
Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
$83.5M
Market Cap • 10/23/2026
2018
(8 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
15,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,1
EPS
—
Market Cap
Market Cap
83,5M
EV
75M
EV/Revenue
13,8
EV/EBITDA
-1,5
EV/EBIT
-1,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-59,2%
Total Yield
-59,2%
Payout
0%
Retained Earnings
-312,7M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
99%
Capex/Revenue
5,8%
Capex/D&A
36%
Capex/OCF
-0,7%
SBC/OCF
—
% PPE
5,7%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
28,6%
CAGR Net Income 5Y
29,1%
CAGR EPS 5Y
-8,1%
CAGR OCF 5Y
39,6%
Leverage
N.D./EBITDA
0,2
Debt/Equity
0%
Current Ratio
1,3
Quick Ratio
1,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!